TT&A advised Merrill Lynch (Singapore) Pte. Ltd., Citigroup  Global Markets Singapore Pte. Ltd., The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch, Standard Chartered Bank (Singapore) Limited, BNP Paribas and Mizuho Securities (Singapore) Pte. Ltd. (the “Initial Purchasers”) in connection with the issue and sale of USD 800 million 6.67% Senior Secured Notes due 2029 by Biocon Biologics Global plc, a wholly owned step down subsidiary of Biocon Biologics Limited.

The transaction represents the first US$ bond issuance by a biopharmaceutical company in Asia-Pacific, and the largest debut issuance from a high yield rated issuer from India in the past 10 years. It is also the debut overseas bond issuance by the Biocon group.

TT&A Team: Rahul Gulati & Priyanka Kumar – Partners; Saara Ahmed – Managing Associate; Aakash Puttige – Senior Associate and  Shivani Iyer & Sushil Joon – Associates